- Home
- SRFM vs IPHA Comparison
SRFM vs IPHA Comparison
Compare SRFM & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRFM
- IPHA
- Stock Information
- Founded
- SRFM 2011
- IPHA 1999
- Country
- SRFM United States
- IPHA France
- Employees
- SRFM N/A
- IPHA N/A
- Industry
- SRFM Transportation Services
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- SRFM Consumer Discretionary
- IPHA Health Care
- Exchange
- SRFM Nasdaq
- IPHA Nasdaq
- Market Cap
- SRFM 185.9M
- IPHA 160.1M
- IPO Year
- SRFM 2023
- IPHA 2019
- Fundamental
- Price
- SRFM $4.53
- IPHA $1.94
- Analyst Decision
- SRFM Buy
- IPHA Hold
- Analyst Count
- SRFM 4
- IPHA 2
- Target Price
- SRFM $5.75
- IPHA $2.00
- AVG Volume (30 Days)
- SRFM 1.7M
- IPHA 15.1K
- Earning Date
- SRFM 11-13-2025
- IPHA 09-17-2025
- Dividend Yield
- SRFM N/A
- IPHA N/A
- EPS Growth
- SRFM N/A
- IPHA N/A
- EPS
- SRFM N/A
- IPHA N/A
- Revenue
- SRFM $107,372,000.00
- IPHA $14,839,695.00
- Revenue This Year
- SRFM N/A
- IPHA $350.96
- Revenue Next Year
- SRFM $18.06
- IPHA $32.92
- P/E Ratio
- SRFM N/A
- IPHA N/A
- Revenue Growth
- SRFM N/A
- IPHA N/A
- 52 Week Low
- SRFM $1.10
- IPHA $1.29
- 52 Week High
- SRFM $9.91
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- SRFM 54.30
- IPHA 38.72
- Support Level
- SRFM $4.13
- IPHA $1.93
- Resistance Level
- SRFM $4.57
- IPHA $2.19
- Average True Range (ATR)
- SRFM 0.27
- IPHA 0.11
- MACD
- SRFM 0.04
- IPHA -0.01
- Stochastic Oscillator
- SRFM 84.88
- IPHA 13.19
About SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.